Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: Systematic review and meta-analysis of cardiovascular outcomes trials

Circulation

Volumn 139, Issue 17, 2019, Pages 2022-2031

  Zelniker, Thomas A ^a   Wiviott, Stephen D ^a   Raz, Itamar ^b   Im, Kyungah ^a   Goodrich, Erica L ^a   Furtado, Remo H M ^a   Bonaca, Marc P ^a   Mosenzon, Ofri ^b   Kato, Eri T ^c   Cahn, Avivit ^b   Bhatt, Deepak L ^a   Leiter, Lawrence A ^d   McGuire, Darren K ^e   Wilding, John P H ^f   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

diabetes mellitus, type 2; glucagon like peptide 1 receptor agonists; meta analysis; sodium glucose co; transporter 2 inhibitors

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE RECEPTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; DISEASE EXACERBATION; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HAZARD RATIO; HEART FAILURE; HUMAN; KIDNEY DISEASE; MACROALBUMINURIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; AGED; ATHEROSCLEROSIS; COMPARATIVE STUDY; COMPLICATION; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; FEMALE; MALE; MIDDLE AGED; PHARMACOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GLUCAGON-LIKE PEPTIDE RECEPTORS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85065306608     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.118.038868     Document Type: Article

References (37)

1. U.S. Food and Drug Administration Guidance for Industry: Diabetes Mellitus: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed November 24, 2017
2. European Medical Agency Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus-revision-en.pdf. Accessed November 10, 2018
3. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016 375 311 322. doi: 10.1056/NEJMoa1603827
4. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 375 1834 1844. doi: 10.1056/NEJMoa1607141
5. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018 392 1519 1529. doi: 10.1016/S0140-6736(18)32261-X
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373 2117 2128. doi: 10.1056/NEJMoa1504720
7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 377 644 657. doi: 10.1056/NEJMoa1611925
8. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB, Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018 41 2669 2701. doi: 10.2337/dci18-0033
9. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS, 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018 72 3200 3223. doi: 10.1016/j.jacc.2018.09.020
10. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019 393 31 39. doi: 10.1016/S0140-6736(18)32590-X
11. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR, EXSCEL Study Group Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018 6 105 113. doi: 10.1016/S2213-8587(17)30412-6
12. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015 162 777 784. doi: 10.7326/M14-2385
13. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015 4 1. doi: 10.1186/2046-4053-4-1
14. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015 350 g7647. doi: 10.1136/bmj.g7647
15. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group; Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011 343 d5928. doi: 10.1136/bmj.d5928
16. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB, LEADER Steering Committee and Investigators Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017 377 839 848. doi: 10.1056/NEJMoa1616011
17. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH, Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2018 6 859 869. doi: 10.1016/S2213-8587(18)30268-7
18. Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona BG, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman PK, Poulter NR, Ramachandran A, Tankova T, Zinman B, Hernandez AF, Holman RR, Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes 2018 67 522P. doi: 10.1016/S2213-8587(17)30412-6
19. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016 375 323 334. doi: 10.1056/NEJMoa1515920
20. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B, Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018 6 691 704. doi: 10.1016/S2213-8587(18)30141-4
21. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE-TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019 380 347 357. doi: 10.1056/NEJMoa1812389
22. Hartung J, Knapp G, A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 2001 20 3875 3889. doi: 10.1002/sim.1009
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG, Measuring inconsistency in meta-analyses. BMJ 2003 327 557 560. doi: 10.1136/bmj.327.7414.557
24. Viechtbauer W, Conducting meta-analyses in R with the metafor Package. J Stat Softw 2010 36 48. doi: 10.18637/jss.v036.i03
25. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017 377 1228 1239. doi: 10.1056/NEJMoa1612917
26. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015 373 2247 2257. doi: 10.1056/NEJMoa1509225
27. Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E, Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial. JAMA Cardiol 2018 3 155 163. doi: 10.1001/jamacardio.2017.4228
28. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009 20 1813 1821. doi: 10.1681/ASN.2008121270
29. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP, ERA-EDTA Diabesity Working Group Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2015 3 382 391. doi: 10.1016/S2213-8587(15)00094-7
30. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME, Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014 37 2864 83. doi: 10.2337/dc14-1296
31. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V, CREDENCE study investigators The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017 46 462 472. doi: 10.1159/000484633
32. Zelniker TA, Braunwald E, Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018 72 1845 1855. doi: 10.1016/j.jacc.2018.06.040
33. Sattar N, Petrie MC, Zinman B, Januzzi JL Jr., Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol 2017 69 2646 2656. doi: 10.1016/j.jacc.2017.04.014
34. Drucker DJ, The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016 24 15 30. doi: 10.1016/j.cmet.2016.06.009
35. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016 134 752 772. doi: 10.1161/CIRCULATIONAHA.116.021887
36. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona-Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw J, Sheu WH, Temelkova-Kurktschiev T, REWIND Trial Investigators Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 2018 20 42 49. doi: 10.1111/dom.13028
37. Press Release Trulicity® (Dulaglutide) Demonstrates Superiority in Reduction of Cardiovascular Events for Broad Range of People with Type 2 Diabetes. 2018. https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-demonstrates-superiority-reduction. Accessed November 8, 2018